Icatibant Zentiva

Icatibant Acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as an injection solution in single-use prefilled syringes for subcutaneous use. It is approved in the European Union for the treatment of acute attacks of hereditary angioedema (C1‑inhibitor deficiency) and is available by prescription only.

GNH USA supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for specialty medicines. Our network ensures compliance with local regulations and cold‑chain logistics where required.

Icatibant Zentiva is used to treat conditions caused by excessive bradykinin activity, primarily hereditary angioedema.

- Hereditary angioedema type I (C1‑inhibitor deficiency): Provides rapid relief of swelling during acute attacks. - Hereditary angioedema type II (dysfunctional C1‑inhibitor): Reduces attack severity and duration. - Acute hereditary angioedema attacks (any type): Controls sudden swelling episodes and shortens recovery time.

Icatibant Zentiva may cause a range of adverse reactions, most of which are related to the injection site or systemic response.

Common Side Effects: - Injection site pain: Discomfort at the site of subcutaneous administration. - Injection site erythema: Redness around the injection area. - Nausea: Mild to moderate feeling of queasiness. - Headache: Transient head discomfort. - Dizziness: Light‑headed sensation shortly after dosing. - Flushing: Warmth and reddening of the skin.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Including rash, itching, or swelling beyond the injection site. - Anaphylaxis: Rapid, life‑threatening allergic response requiring immediate medical attention. - Hypotension: Marked drop in blood pressure that may cause fainting. - Angioedema unrelated to HAE: Unexpected swelling of lips, tongue, or airway. - Injection site necrosis: Tissue death at the injection site, though very uncommon.

Before using Icatibant Zentiva, clinicians should consider several safety measures.

- Assess patient history for hypersensitivity: Avoid use in individuals with known allergy to icatibant or its excipients. - Monitor for severe abdominal pain: May indicate a serious reaction requiring evaluation. - Use with caution in patients on ACE inhibitors: Concomitant therapy could affect bradykinin pathways. - Avoid in patients with known bradykinin B2 receptor hypersensitivity: The drug may exacerbate reactions. - Pregnancy and lactation: Safety not established; weigh potential benefits against unknown risks. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant Zentiva can interact with other medicines that influence bradykinin or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: May reduce the therapeutic benefit of icatibant by increasing bradykinin levels. - Other bradykinin B2 receptor antagonists: Concurrent use can lead to additive pharmacologic effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: May increase the frequency of hereditary angioedema attacks. - Immunosuppressive agents: Monitor for heightened infection risk when combined with icatibant therapy.